proteas
candid
biomark
therapeut
target
mani
diseas
sensit
robust
techniqu
need
quantifi
proteolyt
activ
within
complex
biolog
milieu
hypothes
combinatori
proteas
substrat
librari
could
use
effect
identifi
similar
differ
serum
bronchoalveolar
lavag
fluid
balf
two
bodi
fluid
clinic
import
develop
target
therapi
diagnost
use
concis
librari
fluorogen
probe
map
proteas
substrat
specif
serum
balf
guinea
pig
differ
proteolyt
fingerprint
two
fluid
strike
serum
proteas
cleav
substrat
contain
cation
residu
prolin
wherea
balf
proteas
cleav
substrat
contain
aliphat
aromat
residu
notabl
cleavag
prolinecontain
substrat
domin
proteas
activ
human
guinea
pig
serum
substrat
profil
approach
provid
foundat
quantit
comparison
proteas
specif
complex
biolog
sampl
proteas
garner
interest
therapeut
target
divers
array
human
diseas
proteas
inhibitor
approv
treatment
hypertens
angiotensin
convert
enzym
hiv
infect
hiv
proteas
thrombosi
thrombin
condit
inhibitor
also
develop
valid
proteas
target
condit
type
diabet
osteoporosi
well
mani
viral
parasit
bacteri
infect
addit
proteas
promis
biomark
mani
cancer
respiratori
diseas
neurolog
disord
key
challeng
identif
character
diseaserelev
proteas
measur
enzymat
activ
milieu
serum
biolog
fluid
multitud
proteas
hydrolas
act
concert
mass
spectrometri
ms
base
proteom
activitybas
protein
profil
two
power
techniqu
capabl
detect
proteas
cleavag
product
within
complex
mixtur
msbase
proteas
profil
techniqu
develop
detect
cleavag
synthet
affinitylabel
substrat
serum
case
activitybas
protein
profil
activ
sitedirect
probe
use
select
enrich
particular
enzym
class
famili
metalloproteas
complement
method
assess
global
proteolyt
specif
fingerprint
complex
sampl
could
reveal
two
import
piec
inform
access
techniqu
character
abund
focu
select
proteas
first
broad
quantit
comparison
across
proteolyt
specif
made
second
differ
observ
would
miss
bias
experi
focus
specif
proteas
one
method
measur
proteas
enzym
kinet
determin
substrat
specif
involv
use
substratederiv
peptid
probe
remain
optic
silent
uncleav
state
fluoresc
upon
enzymat
cleavag
assay
proteas
divers
combinatori
probe
librari
substrat
specif
precis
defin
probe
librari
use
great
success
determin
properti
purifi
recombin
proteas
repres
major
proteas
class
howev
approach
use
profil
proteolyt
activ
biolog
fluid
serum
hypothes
combinatori
proteas
substrat
librari
could
use
effect
identifi
similar
differ
serum
bronchoalveolar
lavag
fluid
balf
two
bodi
fluid
clinic
import
develop
target
therapi
diagnost
use
concis
librari
intern
quench
fluorogen
probe
iqfp
map
endoproteas
specif
serum
balf
guinea
pig
probe
librari
contain
sequenc
mcaglyglyglyxaayaazaaglyglydpalysli
mca
correspond
acid
fluorophor
dpa
correspond
n
acid
quencher
figur
two
ctermin
lysin
includ
improv
aqueou
solubl
hydrophob
sequenc
xaa
yaa
zaa
correspond
variabl
residu
compris
equimolar
mixtur
similar
amino
acid
alav
aspglu
phetyr
ileleu
lysarg
asngln
serthr
pro
amino
acid
exclud
librari
either
chemic
incompat
cy
met
interfer
fluoresc
trp
rare
found
proteas
cleavag
site
librari
previous
valid
substrat
specif
profil
purifi
recombin
endoproteas
repres
major
proteas
class
includ
trypsin
pepsin
well
librari
contain
equimolar
mixtur
one
seven
amino
acid
pair
prolin
three
differ
variabl
posit
thu
well
librari
contain
equimolar
mixtur
eight
individu
peptid
unless
one
variabl
posit
contain
pro
case
well
contain
fewer
sequenc
array
six
micropl
iqfp
occupi
well
plate
except
well
plate
iqfp
occupi
column
well
thu
column
lower
plate
appear
black
heatmap
shown
figur
librari
synthesi
qualiti
control
procedur
describ
detail
elsewher
iqfp
librari
obtain
mimotop
clayton
victoria
australia
unless
otherwis
indic
chemic
reagent
sigmaaldrich
st
loui
mo
usa
vwr
scientif
radnor
pa
usa
content
librari
well
nmol
total
peptidewel
dissolv
acetonitril
acn
ultrapur
water
dilut
sterilefilt
serin
proteas
buffer
mm
hepe
mm
nacl
mm
cacl
ph
subdivid
two
aliquot
assay
conduct
buffer
condit
commonli
use
character
serin
proteas
abund
serum
balf
assay
one
aliquot
solut
transfer
low
volum
black
micropl
molecular
devic
sunnyval
ca
usa
min
appropri
biolog
sampl
ad
micropl
contain
iqfp
librari
biolog
sampl
thaw
ice
immedi
prior
assay
complement
preserv
normal
human
serum
obtain
innov
research
novi
mi
usa
store
use
use
suppli
guinea
pig
balf
serum
gener
provid
tom
patterson
univers
texa
health
scienc
center
san
antonio
sampl
collect
immunosuppress
male
hartley
guinea
pig
kg
charl
river
laboratori
wilmington
usa
proteolyt
activ
fluid
deriv
immunosuppress
anim
interest
immunodefici
key
risk
factor
mani
infect
immunosuppress
anim
import
model
diseas
immunosuppress
regimen
administ
day
sampl
collect
day
sampl
store
ship
overnight
dri
ice
immedi
place
store
use
guinea
pig
balf
serum
aliquot
multipl
anim
pool
immedi
prior
assay
anim
micropl
human
serum
pool
guinea
pig
serum
sampl
dilut
assay
buffer
prior
use
pool
guinea
pig
balf
sampl
use
undilut
protein
content
pool
guinea
pig
balf
serum
prepar
mgml
mgml
respect
determin
bicinchonin
acid
bca
pierc
rockford
il
usa
biorad
laboratori
hercul
ca
usa
protein
assay
timeresolv
fluoresc
data
obtain
analyst
ht
instrument
molecular
devic
use
excit
emiss
filter
nm
respect
read
taken
everi
min
h
human
serum
h
guinea
pig
serum
balf
room
temperatur
fluoresc
enhanc
observ
well
contain
iqfp
well
contain
control
medium
data
shown
raw
fluoresc
intens
fi
data
export
microsoft
excel
end
point
fluoresc
intens
fold
chang
valu
calcul
f
final
f
initi
init
h
final
h
human
serum
h
guinea
pig
serum
balf
well
consid
posit
greater
increas
fi
observ
heatmap
gener
fold
chang
data
squar
correspond
singl
assay
well
stack
micropl
heatmap
builder
ashley
lab
stanford
univers
corr
guinea
pig
balf
serum
librari
screen
data
analyz
deriv
kinet
rate
cleavag
linear
nonlinear
regress
well
end
point
fluoresc
fold
chang
linear
slope
nonlinear
rate
data
deriv
regress
analys
graphpad
prism
nonlinear
regress
onephas
exponenti
associ
model
use
follow
paramet
leastsquar
fit
k
maximum
iter
correl
analys
three
quantif
method
end
point
fluoresc
fold
chang
linear
slope
nonlinear
rate
perform
pearson
product
moment
correl
coeffici
calcul
sigmaplot
deconvolut
select
iqfp
motif
proteolyt
cleavag
individu
iqfp
assay
describ
librari
screen
procedur
modif
iqfp
custom
synthes
confirm
ms
provid
lyophil
powder
mimotop
iqfp
stock
solut
prepar
mm
dmso
addit
dmso
peptid
store
control
experi
presenc
dmso
low
level
use
studi
affect
fluoresc
data
shown
work
dilut
iqfp
ad
balf
serum
well
low
volum
black
micropl
timeresolv
fluoresc
data
record
describ
assay
well
contain
iqfp
hepe
buffer
buffer
composit
describ
balf
serum
fold
chang
h
calcul
f
final
f
initi
two
iqfp
demonstr
greatest
extent
cleavag
select
librari
well
select
addit
character
effect
photobleach
address
inclus
control
contain
uncleav
peptid
throughout
experi
well
kinet
measur
fluoresc
cleav
uncleav
control
peptid
iqfp
contain
amino
acid
sequenc
alathrglu
cleav
either
balf
serum
includ
addit
neg
control
determin
effect
classspecif
proteas
inhibitor
cleavag
select
iqfp
balf
serum
proteas
cleavag
assay
perform
describ
presenc
follow
inhibitor
mm
benzenesulfonyl
fluorid
aebsf
serin
proteas
mm
edta
metalloproteas
cystein
proteas
pepstatin
aspart
proteas
determin
limit
detect
individu
proteas
balf
serum
recombin
human
prolyl
oligopeptidas
r
system
minneapoli
mn
usa
select
titrat
balf
balf
devoid
prolyl
endopeptidas
specif
librari
screen
experi
prolyl
oligopeptidas
activ
detect
balf
supplementari
figur
iqfp
cleavag
site
determin
identif
ctermin
iqfp
fragment
matrixassist
laser
desorpt
ioniz
timeofflight
ms
malditof
ms
conclus
proteas
assay
describ
remov
desalt
concentr
solid
phase
extract
micropipet
tip
ziptip
millipor
billerica
usa
accord
manufactur
instruct
sampl
elut
directli
onto
maldi
target
plate
airdri
matrix
solut
acid
water
acetonitril
trifluoroac
etic
acid
subsequ
spot
top
sampl
allow
dri
spectra
acquir
abi
maldi
toftof
hybrid
mass
spectromet
appli
biosystem
carlsbad
ca
usa
intact
parent
peptid
identifi
analog
procedur
control
well
contain
iqfp
buffer
lack
balf
serum
cleavag
site
assign
compar
observ
peak
calcul
expect
mass
correspond
cleavag
possibl
site
sought
determin
proteas
substrat
specif
profil
use
identifi
differ
proteolyt
fingerprint
two
clinic
import
fluid
serum
balf
select
balf
serum
comparison
sever
reason
first
stark
contrast
two
fluid
may
allow
method
establish
verifi
confid
second
balf
serum
clinic
relev
diagnosi
therapi
numer
diseas
import
serum
well
known
balf
obtain
lavag
lung
buffer
salin
import
sampl
clinic
laboratori
evalu
mani
respiratori
diseas
third
studi
establish
proteas
specif
signatur
serv
baselin
futur
analysi
diseas
sampl
much
like
msderiv
baselin
proteom
often
referenc
later
investig
diseas
proteom
fourth
inform
regard
differenti
proteolyt
specif
balf
serum
may
use
design
optim
tissuespecif
prodrug
drug
deliveri
system
imag
contrast
agent
assess
reproduc
iqfp
librari
screen
procedur
first
assay
pool
normal
human
serum
two
independ
experi
figur
bd
proteas
specif
fingerprint
visual
heatmap
format
bright
pseudocolor
squar
repres
extent
cleavag
probe
substrat
correspond
well
express
fluoresc
fold
chang
figur
similar
two
independ
human
serum
screen
qualit
evid
comparison
heatmap
linear
regress
analysi
support
relationship
two
data
set
r
point
fall
outsid
predict
interv
figur
seventytwo
total
posit
well
identifi
experi
found
experi
found
experi
heterogen
microtit
plate
librari
synthesi
unlik
explan
modest
variabl
librari
subject
rigor
qualiti
control
like
explan
involv
inher
biolog
variabl
aris
differ
donor
contribut
two
independ
lot
pool
serum
complet
list
sequenc
motif
cleav
human
serum
report
supplementari
tabl
compar
assess
proteolyt
profil
pool
balf
serum
guinea
pig
visual
heatmap
format
proteas
specif
fingerprint
guinea
pig
balf
serum
strikingli
differ
figur
observ
stark
contrast
perform
rigor
analysi
amino
acid
distribut
abund
motif
cleav
sampl
figur
balf
proteas
preferenti
cleav
substrat
contain
aliphat
aromat
amino
acid
notabl
phetyr
hit
xaa
hit
yaa
hit
zaa
ileleu
hit
xaa
hit
yaa
hit
yaa
figur
substrat
organ
motif
compris
five
assay
well
two
fix
posit
one
variabl
posit
substrat
motif
cleav
balf
serum
contain
phetyr
ileleu
one
fix
posit
motif
highest
mean
fold
chang
shown
figur
cation
residu
argli
almost
complet
absent
substrat
sequenc
cleav
balf
contrast
serum
proteas
cleav
substrat
contain
aliphat
aromat
residu
much
lesser
extent
cleav
substrat
contain
cation
residu
argli
quit
strongli
hit
xaa
hit
yaa
hit
zaa
figur
notabl
howev
prolin
preval
among
substrat
cleav
serum
particularli
xaa
posit
hit
xaa
hit
yaa
hit
zaa
extent
cleavag
prolinecontain
substrat
quantifi
fluoresc
fold
chang
consider
greater
substrat
contain
prolin
motif
cleav
serum
balf
top
contain
prolin
xaa
posit
complet
list
sequenc
motif
cleav
balf
serum
report
supplementari
tabl
linear
nonlinear
regress
analys
provid
inform
regard
kinet
rate
cleavag
reflect
end
point
fluoresc
fold
chang
measur
supplementari
tabl
overal
cleavag
rate
correl
well
end
point
fold
chang
data
although
nonlinear
regress
fail
converg
well
cleav
lesser
extent
end
point
fluoresc
fold
chang
sequenc
cleav
balf
strong
posit
correl
linear
slope
end
point
fluoresc
observ
r
p
wherea
nonlinear
rate
end
point
fluoresc
posit
correl
poor
signific
r
p
linear
slope
nonlinear
rate
fail
show
posit
correl
r
p
supplementari
figur
sequenc
cleav
serum
strong
posit
correl
observ
three
comparison
p
supplementari
figur
cleavag
rate
fell
within
rang
h
balf
serum
proteas
except
popul
sequenc
cleav
much
rapidli
serum
proteas
figur
e
f
rapidli
cleav
sequenc
contain
pro
xaa
posit
provid
evid
predomin
procleav
proteas
serum
clarifi
substrat
specif
balf
serum
proteas
synthes
individu
peptid
correspond
two
repres
well
cleav
balf
serum
librari
screen
well
deconvolut
determin
cleavag
activ
individu
constitu
peptid
figur
balf
proteas
exhibit
unambigu
cleavag
prefer
select
motif
figur
b
among
ileleuphetyrphetyr
sequenc
leuphetyr
optim
tyr
strongli
prefer
zaa
posit
among
serthrileleuasngln
sequenc
optim
sequenc
serleugln
ser
strongli
prefer
xaa
posit
optim
sequenc
serum
proteas
motif
proasnglnalav
proasnglnpro
proasnala
proglnpro
respect
figur
c
two
serum
motif
exhibit
clear
prefer
yaa
zaa
posit
four
motif
top
two
sequenc
select
character
cleavag
individu
synthes
peptid
balf
serum
also
confirm
malditof
ms
case
expect
parent
uncleav
peptid
identifi
control
experi
observ
ctermin
cleavag
fragment
correspond
least
one
cleavag
site
seven
eight
peptid
monitor
supplementari
tabl
sever
sequenc
exhibit
multipl
cleavag
site
surpris
given
multipl
activ
proteas
like
present
biotechniqu
focu
proteom
balf
serum
analyz
cleavag
prolinecontain
motif
serum
identifi
fragment
correspond
cleavag
substrat
prolin
support
possibl
prolyl
endopeptidas
may
respons
activ
one
unexpect
result
identif
fragment
correspond
cleavag
proasnpro
proglnpro
posit
prolyl
endopeptidas
known
cleav
ctermin
side
prolin
residu
howev
possibl
aminopeptidas
hydrolyz
asn
gln
n
terminu
follow
cleavag
bond
gener
fragment
observ
balf
predomin
proteas
cleav
aliphat
aromat
residu
three
variabl
posit
librari
xaa
yaa
zaa
indic
presenc
proteas
repertoir
distinct
serum
although
balf
serum
differ
overal
composit
degre
overlap
exist
result
passiv
facilit
transport
blood
protein
alveolar
space
stark
distinct
balf
serum
proteolyt
profil
particularli
absenc
pro
argli
cleavag
specif
balf
may
result
inhibit
degrad
serumderiv
proteas
lung
environ
addit
reduc
cleavag
substrat
contain
cation
residu
balf
may
due
lower
abund
proteas
associ
clot
complement
cascad
partial
inhibit
balf
proteas
presenc
serin
proteas
inhibitor
aebsf
metalloproteas
inhibitor
edta
indic
role
proteas
two
class
cleavag
supplementari
figur
mani
abund
serin
proteas
serum
includ
kallikrein
thrombin
constitu
complement
cascad
exhibit
prefer
substrat
contain
cation
amino
acid
inde
observ
cation
residu
preval
substrat
cleav
guinea
pig
serum
figur
notabl
cleavag
pattern
human
serum
close
match
guinea
pig
serum
although
overal
cleavag
activ
human
serum
lower
perhap
due
differenti
process
commerci
obtain
human
serum
prepar
supplementari
tabl
similar
human
guinea
pig
serum
proteas
specif
fingerprint
support
possibl
studi
nonhuman
sampl
provid
use
inform
translat
human
proteas
cleavag
prolinecontain
substrat
serum
predomin
term
amino
acid
frequenc
extent
cleavag
figur
sever
solubl
prolyl
endopeptidas
includ
prolyl
oligopeptidas
antiplasmincleav
enzym
present
serum
enzym
regul
action
numer
bioactiv
peptid
includ
substanc
p
thyotropinreleas
hormon
argininevasopressin
angiotensin
ii
chang
serum
prolyl
endopeptidas
activ
report
numer
neurolog
diseas
prolyl
endopeptidas
may
particip
inflammatori
pathway
well
knowledg
extent
prolyl
endopeptidas
activ
serum
comparison
proteas
report
previous
data
indic
prolyl
endopeptidas
preval
serum
support
continu
effort
determin
physiolog
role
larg
number
librari
well
cleav
either
serum
balf
supplementari
tabl
sequenc
contain
disproportion
frequenc
aspglu
asngln
residu
uncleav
sequenc
contain
least
one
two
surpris
aspglu
residu
rel
uncommon
among
proteas
substrat
although
possibl
sequenc
contain
particular
residu
simpli
uncleav
synthet
iqfp
format
explan
unlik
asnglncontain
iqfp
sequenc
previous
found
cleav
also
frequent
among
uncleav
librari
well
sequenc
contain
pro
yaa
posit
percent
uncleav
sequenc
suggest
serum
balf
proteas
recogn
procontain
sequenc
preferenti
pro
adjac
gli
residu
xaa
zaa
posit
despit
promis
approach
import
caveat
note
design
librari
restrict
identif
endoproteas
also
exopeptidas
may
subsequ
act
cleav
iqfp
malditof
msderiv
inform
regard
cleavag
site
may
reflect
action
multipl
proteas
addit
activ
proteas
inhibitor
serum
biolog
environ
depend
buffer
concentr
condit
relat
sampl
prepar
thu
ex
vivo
observ
may
alway
accur
repres
vivo
situat
similarli
synthet
octapeptid
sequenc
may
recapitul
fold
structur
endogen
substrat
nonetheless
ex
vivo
analysi
typic
first
step
identif
character
proteas
serum
biolog
fluid
substrat
specif
profil
complement
exist
proteom
techniqu
assess
differ
proteas
specif
complex
sampl
measur
abund
alon
may
suffici
identif
diagnost
therapeut
target
identifi
proteas
may
inact
proteolyt
degrad
moreov
proteas
inhibitor
abund
serum
lung
proteas
may
present
inactiv
respect
inhibitor
although
small
sequenc
solidphas
librari
previous
use
detect
proteolyt
specif
clinic
blood
sampl
biotechniqu
focu
proteom
approach
expand
probe
sequenc
space
permit
physiolog
solutionphas
kinet
compar
studi
msbase
exoproteas
substrat
profil
recent
suggest
cancer
biomark
discoveri
well
support
approach
proteolyt
specif
interest
identifi
respons
proteas
identifi
use
activ
sitedirect
probe
design
known
substrat
specif
demonstr
saghatelian
cowork
select
isol
metalloproteas
summari
develop
simpl
robust
method
map
proteolyt
specif
complex
biolog
fluid
substrat
identifi
use
method
may
serv
sensor
diagnosi
imag
purpos
scaffold
focus
synthesi
substrat
inhibitor
probe
design
robust
assay
inhibitor
trigger
control
drug
deliveri
